Atirmociclib and fulvestrant for patients with HR-positive/HER2-negative advanced or metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial ☆

Annals of Vascular Surgery · Elsevier

Аннотация

Publication date: Available online 24 October 2026 Source: Annals of Oncology Author(s): A. Giordano, B. Xu, T. Yoshinami, C.-S. Huang, Y.H. Park, G.L. Lerzo, H. Li, A. Shai, G. Garnica Jaliffe, M. Itoh, A. Williams, S. Goel, S.-A. Im, P. Cobb, M. Golmakani, F. Liu, R.A. Moss, A. Vana, M. Ignatiadis, H.S. Rugo

Читать у издателя →

Похожие статьи